List of works - Federico Gatto

Aggressive and Malignant Prolactinomas

scientific article published on 24 January 2019

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

scientific article

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

scientific article published on 13 August 2019

Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells

scientific article published on 01 February 2019

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

scientific article published on 5 November 2013

Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?

article

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

scientific article published on 01 September 2019

Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients

scientific article published on 31 August 2019

Does pasireotide directly modulate skeletal muscle metabolism?

scientific article

Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.

scientific article

Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database

scientific article published on 24 May 2018

Hormone receptors analysis in idiopathic progressive subglottic stenosis

scientific article

Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy

scientific article published on 13 July 2011

Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly

scientific article published on 01 November 2012

Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center

scientific article published on 17 May 2015

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

scientific article published on 13 March 2017

In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5

scientific article published on 18 November 2010

Left Ventricular Mass Reduction by a Low-Sodium Diet in Treated Hypertensive Patients

scientific article published on 30 November 2020

Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.

scientific article published on 17 February 2016

Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives

scientific article

Novel chimeric somatostatin analogs: facts and perspectives.

scientific article published on April 2007

Octreotide-Resistant Acromegaly: Challenges and Solutions

scientific article published on 05 May 2020

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

scientific article published on 01 March 2019

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors.

scientific article published on 2 August 2016

Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.

scientific article

Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

scientific article

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

scientific article

Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.

scientific article published on 10 September 2010

Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain

scientific article published on 19 April 2020

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

scientific article published on 25 July 2016

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

scientific article published on 27 September 2010

Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies

scientific article published on 18 June 2020

Somatostatin receptor ligands in the treatment of acromegaly

scientific article published on 7 February 2017

Somatostatin receptor pathophysiology in the neuroendocrine system

scientific article published on 01 March 2013

The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology

scientific article published on 13 January 2009

The role of somatostatin and dopamine D2 receptors in endocrine tumors

scientific article published on December 2011

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.

scientific article published on 29 October 2013

List of works by Federico Gatto

Aggressive and Malignant Prolactinomas

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients

Does pasireotide directly modulate skeletal muscle metabolism?

Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.

Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database

Hormone receptors analysis in idiopathic progressive subglottic stenosis

Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy

Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly

Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5

Left Ventricular Mass Reduction by a Low-Sodium Diet in Treated Hypertensive Patients

Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.

Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives

Novel chimeric somatostatin analogs: facts and perspectives.

Octreotide-Resistant Acromegaly: Challenges and Solutions

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors.

Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.

Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.

Sodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real Villain

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies

Somatostatin receptor ligands in the treatment of acromegaly

Somatostatin receptor pathophysiology in the neuroendocrine system

The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology

The role of somatostatin and dopamine D2 receptors in endocrine tumors

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.